FDA grants full approval to Pfizer COVID-19 vaccine
On Aug. 23, 2021, the Food and Drug Administration (FDA) granted full approval to the Pfizer-BioNTech vaccine, marketed as Comirnaty, for individuals age 16 and older. The vaccine is available under emergency use authorization for individuals ages 12-15.

FDA authorized third dose of COVID-19 vaccine for certain individuals
On Aug. 12, the FDA authorized an additional dose of mRNA vaccine (Pfizer or Moderna) for moderately to severely immunocompromised people due to a medical condition or receipt of immunosuppressive medications or treatments.

Direction for physicians and their patients

  • Physicians should continue to recommend COVID-19 vaccination for all eligible individuals, including women who are pregnant, lactating, trying to conceive or might conceive in the future.
  • Fully vaccinated people who come into close contact with someone with COVID-19 should get tested 3-5 days after the date of the exposure and wear a mask in public indoor settings for 14 days after exposure or until a negative test result.
More information is available in the CDPHE Health Alert Network Broadcast sent on Aug. 26, 2021.

Categories: Communications, ASAP, Resources, COVID